CD5 and mature T-cell and NK-cell non-Hodgkin lymphoma: Additionally, Myeloid Therapeutics’ MT-101 (NCT05138458), an mRNA-engineered CAR-M therapy, has received fast-track designation from the FDA for treating relapsed or refractory CD5-positive peripheral T-cell lymphoma (PTCL).